A phase II clinical trial of irradiated PD-L1 CAR-NK cells with pembrolizumab and N-803 against advanced gastric or head/neck cancer (Table 2) and a phase I dual-targeting HER2 and PD-L1 CAR T cell trial against patients with HER2-positive cancer with pleural or peritoneal metastases are ongoing. Here, ERBB2 is linked to head and neck cancer.